Notably, Tazemetostat, an oral EZH2 inhibitor, has demonstrated favorable tolerability in older patients with advanced solid tumors, including those with genitourinary malignancies (e.g., prostate cancer) (Izutsu et al., 2021). Here, EZH2 is linked to Familial prostate cancer.